WO2013029548A1 - Quinolone compound - Google Patents
Quinolone compound Download PDFInfo
- Publication number
- WO2013029548A1 WO2013029548A1 PCT/CN2012/080753 CN2012080753W WO2013029548A1 WO 2013029548 A1 WO2013029548 A1 WO 2013029548A1 CN 2012080753 W CN2012080753 W CN 2012080753W WO 2013029548 A1 WO2013029548 A1 WO 2013029548A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- optionally substituted
- group
- alkyl
- compound
- substituents selected
- Prior art date
Links
- 0 Cc(cc1*)cc2c1OCO2 Chemical compound Cc(cc1*)cc2c1OCO2 0.000 description 23
- AIHSGQNTBBVGBC-UHFFFAOYSA-N CC(C)C(CC1)=CCN1C1CNCC1 Chemical compound CC(C)C(CC1)=CCN1C1CNCC1 AIHSGQNTBBVGBC-UHFFFAOYSA-N 0.000 description 1
- IVKILQAPNDCUNJ-UHFFFAOYSA-N Cc(cc1)cc2c1nc[s]2 Chemical compound Cc(cc1)cc2c1nc[s]2 IVKILQAPNDCUNJ-UHFFFAOYSA-N 0.000 description 1
- FJLOVPFVTPAEAC-UHFFFAOYSA-N Cc(cc1N2)cc([O]=CC3)c1N3C2=O Chemical compound Cc(cc1N2)cc([O]=CC3)c1N3C2=O FJLOVPFVTPAEAC-UHFFFAOYSA-N 0.000 description 1
- QWYOZDDADAHDKL-UHFFFAOYSA-N Cc(cc1OCC2)cc3c1[n]2nn3 Chemical compound Cc(cc1OCC2)cc3c1[n]2nn3 QWYOZDDADAHDKL-UHFFFAOYSA-N 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Cc1ccccc1 Chemical compound Cc1ccccc1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Definitions
- the present invention relates to quinolone compounds and pharmaceutical use thereof.
- Clostridium difficile infection is associated with consumption of antibiotics which disrupt the normal microbial flora of the gut, allowing Clostridium difficile to establish itself and produce disease.
- antibiotics which disrupt the normal microbial flora of the gut
- EP2177214 Al describes use of ozenoxacin for Clostridium difficile .
- the object of the present invention is to provide a novel quinolone compound which has excellent antimicrobial activity, particularly excellent antimicrobial activity against Clostridium difficile .
- Another object of the present invention is to provide a pharmaceutical composition
- AAD antibiotics-associated diarrhea
- a further object of the present invention is to provide a method for preventing or treating a bacterial infection including AAD such as CDAD, which comprises administering said quinolone compound to a human or an animal .
- the present invention provides a quinolone compound, a pharmaceutical composition comprising said compound, use of said compound, and a method for preventing or treating a bacterial infection, as described in Items 1 to 27 below.
- X is a hydrogen atom or a fluorine atom
- R is a hydrogen atom or alkyl
- R 1 is (1) cyclopropyl optionally substituted by 1 to 3 halogen atoms or (2) phenyl optionally substituted by 1 to 3 halogen atoms ;
- R 2 is a hydrogen atom; alkyl optionally substituted by 1 or 2 substituents selected from the group consisting of a halogen atom and hydroxyl; alkoxy; haloalkoxy; a halogen atom; cyano; cyclopropyl; nitro; amino; formyl; alkenyl or alkynyl; or
- R 1 and R 2 are bonded to form a 5- or 6-membered ring optionally substituted by alkyl;
- X 1 is C (R 5 ) or N
- R 4 is a hydrogen atom or alkyl
- R 5 is (a) a hydrogen atom, (b) a halogen atom,
- R 4 and R 5 are optionally bonded to form a 5- or 6-membered ring optionally substituted by oxo,
- said fused heterocyclic group is optionally substituted by 1 or 2 substituents selected from the group consisting of a halogen atom, cyano, nitro, hydroxy and alkyl,
- X 2 is C (R 8 ) or N
- R 6 , R 7 and R 8 are each independently,
- alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of a halogen atom, alkoxy and amino,
- X 3 and X 4 are N, or
- X 3 is N and X 4 is CR", wherein R" is hydrogen atom, amino, hydroxy, alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of alkoxy and dimethylamino or mercapto, or
- X 3 is CH and X 4 is N
- R' is a hydrogen atom or alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of
- R 6 is as defined above
- alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of a halogen atom, alkylamino, dialkylamino and hydroxy,
- alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of amino, alkoxycarbonylamino, alkylamino and dialkylamino,
- heterocyclylcarbonyl group optionally substituted by alkyl optionally substituted by 1 to 3 halogen atoms
- heterocyclylsulfonyl group optionally substituted by 1 to 3 alkyl
- one of Y 1 , Y 2 , Y 3 and Y 4 is N or N + (-0 ' and the remaining three
- R ' 23 is a hydrogen atom or alkyl
- R ' 24 R 25 R 26 and R are each independently,
- R 28 is a hydrogen atom or hydroxy
- R 29 is a hydrogen atom or alkyl
- X 5 is C (R 11 ) or N
- R 10 R 12 and R are each independently,
- R 11 R 13 and R 15 are each independently,
- R 1U and R 11 are optionally bonded to form a 5- or 6-membered ring optionally substituted by alkyl or oxo
- X 6 is N(R 12 ) and X 7 is CH(R 13 )
- R 12 and R 13 are optionally bonded to form a 5- or 6-membered ring
- alkyl optionally substituted by alkyl, alkoxycarbonyl, carboxy or phenyl, or
- R 18 is a hydrogen atom or alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of a halogen atom and phenyl,
- n 0 or 1
- R 19 , R 20 and R 33 are each independently,
- R 21 is a hydrogen atom or alkyl optionally substituted by alkylamino or
- R°° is (a) a hydrogen atom
- alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of a halogen atom and hydroxy
- U is 0 or S
- R is (a) a hydrogen atom
- R 34 and R 35 are each independently,
- R 34 and R 35 are bonded to form a 6-membered ring optionally substituted by amino or oxo,
- X is a hydrogen atom or a fluorine atom
- R is a hydrogen atom or alkyl
- R 1 is (1) cyclopropyl optionally substituted by 1 to 3 halogen atoms or (2) phenyl optionally substituted by 1 to 3 halogen atoms ;
- R 2 is alkyl, alkoxy, haloalkoxy, a chlorine atom or cyano; or R 1 and R 2 are bonded to form a 5- or 6-membered ring optionally substituted by alkyl; and
- X 1 is C (R 5 ) or N
- R 4 is a hydrogen atom or alkyl
- R 5 is (a) a hydrogen atom
- R 4 and R 5 are optionally bonded to form a 5- or 6-membered ring optionally substituted by oxo,
- said fused heterocyclic group is optionally substituted by 1 or 2 substituents selected from the group consisting of a halogen atom, cyano, nitro, hydroxy and alkyl,
- X 2 is C (R 8 ) or N
- R 6 , R 7 and R 8 are each independently,
- alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of a halogen atom, alkoxy and amino,
- X and X are N, or
- X 3 is N and X 4 is CR", wherein R" is a hydrogen atom, amino, hydroxy, alkyl or mercapto, or
- X 3 is CH and X 4 is N
- R' is a hydrogen atom or alkyl optionally substituted by 1 3 substituents selected from the group consisting of substituted hydroxy and amino, and
- R 6 is as defined above
- alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of a halogen atom, alkylamino, dialkylamino and hydroxy,
- alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of amino, alkoxycarbonylamino, alkylamino and dialkylamino,
- heterocyclylcarbonyl group optionally substituted by alkyl optionally substituted by 1 to 3 halogen atoms
- heterocyclylsulfonyl group optionally substituted by 1 to 3 alkyl
- Y 1 , Y 2 , Y 3 and Y 4 is N or N + (-0 ' the remaining three
- R is a hydrogen atom or alkyl
- R ' 25 R 26 and R are each independently,
- R 28 is a hydrogen atom or hydroxy
- R 29 is a hydrogen atom or alkyl
- X 5 is C (R 11 ) or N
- R 10 R 12 and R are each independently,
- R 11 R 13 and R 15 are each independently,
- alkyl optionally substituted by alkyl, alkoxycarbonyl, carboxy or phenyl, or
- R 18 is a hydrogen atom or alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of a halogen atom and phenyl, and
- R 19 and R 20 are each independently,
- R 21 is a hydrogen atom or alkyl optionally substituted by alkylamino or
- R is (a) a hydrogen atom
- alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of a halogen atom and hydroxy
- alkenyl
- Item 3 The compound of item 1 or 1A, wherein R 3 is a fused heterocyclic group of the formula
- X 1 and R 4 are as defined in item 1, and said fused heterocyclic group is optionally substituted by 1 or 2 substituents selected from the group consisting of a halogen atom, cyano, nitro, hydroxy and alkyl, or a salt thereof.
- Item 4 The compound of item 1 or 1A, wherein R is a
- Item 7 The compound of item 1 or 1A, wherein R is a group of the formula
- alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of a halogen atom, alkylamino, dialkylamino and hydroxy,
- Item 8 The compound of item 1 or 1A, wherein R is 5- pyrimidinyl substituted by 1 or 2 substituents selected from the group consisting of amino, alkylamino, dialkylamino and carboxy, or a salt thereof.
- heterocyclylcarbonyl group optionally substituted by alkyl optionally substituted by 1 to 3 halogen atoms
- heterocyclylsulfonyl group optionally substituted by 3 alkyl
- Y 1 , Y 2 , Y 3 , Y 4 , W and R 24 are as defined in item 1, salt thereof.
- R and R are as defined in item 1, or a salt thereof.
- alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of cyano, alkylamino and dialkylamino,
- alkyl optionally substituted by alkyl, alkoxycarbonyl, carboxy or phenyl, or
- Item 14 The compound of item 1 or 1A, wherein R is a group of the formula
- R 18a is alkyl
- R 19a is (a) a halogen atom
- alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of (i) a halogen atom,
- (k) -CH N-OR 21 wherein R 21 is a hydrogen atom or alkyl optionally substituted by alkylamino or dialkylamino, or
- Item 15 The compound of item 1 or 1A, wherein R is a group of the formula
- R is as defined in item 1, or a salt thereof.
- Item 16 The compound of item 1 or 1A, wherein R is naphthyl or isochromenyl , or a salt thereof.
- Item 17 The compound of item 1 or 1A, wherein R is quinolyl or isoquinolyl, or oxide derivative thereof, or a salt thereof.
- Item 18 The compound of item 1 or 1A, wherein R is hydrogen atom, or a salt thereof.
- Item 19 The compound of item 1 or 1A, wherein R is cyclopropyl, 2-fluorocyclopropyl or 2, 4-difluorophenyl, or a salt thereof.
- Item 20 The compound of item 1 or 1A, wherein R 2 is methyl, methoxy or a chlorine atom, or a salt thereof.
- Item 21 A pharmaceutical composition comprising a compound of item 1 or 1A or a salt thereof and a
- Item 22 An antimicrobial agent comprising a compound of item 1 or 1A or a salt thereof.
- Item 23 A compound of item 1 or 1A or a salt thereof for use as a medicament.
- Item 24 A compound of item 1 or 1A or a salt thereof for use as an antimicrobial agent.
- Item 25 A compound of item 1 or 1A or a salt thereof for use in the prevention or treatment of a bacterial infection.
- Item 26 Use of a compound of item 1 or 1A or a salt thereof for the manufacture of a medicament for preventing or treating a bacterial infection.
- Item 27 A method for preventing or treating a bacterial infection which comprises administering an effective amount of a compound of item 1 or 1A or a salt thereof to a human or an animal .
- the compound of the formula (I) or a salt thereof is administered to a human or an animal .
- compound (I) has excellent antibacterial activity against various gram positive and gram negative bacteria, and is useful for the prevention or treatment of various infectious diseases induced by various bacteria in human, other animals and fish and is also useful as an external antimicrobial or disinfectant agent for medical instruments or the like.
- Fig. 1 is a graph showing the results of the animals administered with compound 2-18 in Experimental Example 2.
- Fig. 2 is a graph showing the results of the animals administered with vancomycin in Experimental Example 2. Detailed Description of the Invention
- halogen atom examples include fluorine atom, chlorine atom, bromine atom, and iodine atom.
- alkyl and “alkyl” moiety in “alkylamino” , “dialkylamino” , “alkylcarbonyl” , “cycloalkylalkylsulfonyl”, “cycloalkylalkyl”, “aminoalkyl” and “alkylsulfonyl” include straight or branched Ci-6 alkyl such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, 1- ethylpropyl, isopentyl, neopentyl, tert-pentyl, hexyl, 1,2,2- trimethylpropyl, 3, 3-dimethylbutyl, 2-ethylbutyl, isohexyl, 3- methylpentyl, etc.
- alkenyl examples include straight or branched C2-6 alkenyl such as vinyl, 1-propenyl, 2-propenyl, 1-butenyl, 2- butenyl, 3-butenyl, l-methyl-2-propenyl, 2-pentenyl, 2-hexenyl, etc .
- alkynyl examples include straight or branched C2-6 alkynyl such as ethynyl, 2-propynyl, 2-butynyl, 3-butynyl, 1- methyl-2-propynyl, 2-pentynyl, 2-hexynyl, etc.
- alkoxy and “alkoxy” moiety in “haloalkoxy” , “alkoxycarbonyl” and “alkoxycarbonylamino” include straight or branched Ci-6 alkoxy such as methoxy, ethoxy, propoxy,
- haloalkoxy examples include straight or branched Ci-6 alkoxy substituted by 1 to 3 halogen atoms. Examples thereof include fluoromethoxy, difluoromethoxy, trifluoromethoxy, chloromethoxy, dichloromethoxy, trichloromethoxy, bromomethoxy, dibromomethoxy, dichlorofluoromethoxy, 2, 2, 2-trifluoroethoxy, 2- chloroethoxy, 3, 3, 3-trifluoropropoxy, 2-chloropropoxy, 3- chloropropoxy, 3-bromopropoxy, 4, 4, 4-trifluorobutoxy, 2- chlorobutoxy, 4-chlorobutoxy, 4-bromobutoxy, 5,5,5- trifluoropentyloxy, 5-chloropentyloxy, 6, 6, 6-trifluorohexyloxy, 6-chlorohexyloxy, etc. Preferable examples thereof include difluoromethoxy.
- alkenyloxy examples include straight or branched C2-6 alkenyloxy such as vinyloxy, 1-propenyloxy, 2-propenyloxy, 1- butenyloxy, 2-butenyloxy, 3-butenyloxy, l-methyl-2-propenyloxy, 2-pentenyloxy, 2-hexenyloxy, etc.
- aryl and “aryl” moiety in “arylsulfonyl” include Ce-14 (preferably C6-10) aryl such as phenyl, naphthyl (e.g., 1-naphthyl, 2-naphthyl ) , etc. Preferable examples thereof include phenyl .
- Examples of "5- to 10-membered aromatic heterocyclic group” and “5- to 10-membered aromatic heterocyclyl” moiety in “5- to 10-membered aromatic heterocyclylcarbonyl group” and “5- to 10-membered aromatic heterocyclylsulfonyl group” include 5- to 10-membered (preferably 5- or 6-membered) aromatic
- heterocyclic group containing 1 to 4 preferably 1 to 3, more preferably 1 or 2) heteroatoms selected from a nitrogen atom, an oxygen atom and a sulfur atom.
- heteroatoms selected from a nitrogen atom, an oxygen atom and a sulfur atom.
- examples thereof include furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl (e.g.,
- Preferable examples thereof include pyrrolyl, imidazolyl, oxazolyl, triazolyl (e.g., 1 , 2 , 3-triazolyl, 1, 2, 4-triazolyl) , tetrazolyl, pyridyl (e.g., 2 -pyridyl, 3-pyridyl, 4-pyridyl), benzimidazolyl, etc.
- alkylamino examples include Ci-6 alkylamino such as methylamino, ethylamino, propylamino, isopropylamino,
- butylamino isobutylamino, sec-butylamino, tert-butylamino, pentylamino, isopentylamino, neopentylamino, tert-pentylamino, hexylamino, etc.
- dialkylamino examples include di (Ci-6 alkyl) amino such as dimethylamino, diethylamino, dipropylamino, diisopropylamino, dibutylamino, diisobutylamino, di (sec-butyl) amino, di (tert- butyl) amino, dipentylamino, di (tert-pentyl) amino, dihexylamino, ethylmethylamino, etc.
- di (Ci-6 alkyl) amino such as dimethylamino, diethylamino, dipropylamino, diisopropylamino, dibutylamino, diisobutylamino, di (sec-butyl) amino, di (tert- butyl) amino, dipentylamino, di (tert-pentyl) amino, dihexylamino, ethylmethylamino, etc.
- aminoalkyl examples include amino-Ci-6 alkyl such as aminomethyl, 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, 5- aminopentyl, 6-aminohexyl, etc.
- cycloalkyloxy include C3-8 cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, norbornanyl (e.g., 2-norbornanyl) , etc.
- cycloalkylalkyl examples include C3-8 cycloalkyl-Ci_6 alkyl such as cyclopropylmethyl, cyclobutylmethyl,
- cyclic amino group includes a 4- to 7- membered (preferably 5- or 6-membered) cyclic amino group containing one nitrogen atom and optionally further containing one heteroatom selected from a nitrogen atom, an oxygen atom and a sulfur atom.
- Examples thereof include 1-azetidinyl, 1- pyrrolidinyl, 1-imidazolidinyl, 1-pyrazolidinyl, piperidino, 1- piperazinyl, morpholino, thiomorpholino, 1-azepanyl, 1,4- oxazepan-4-yl, etc.
- Preferable examples thereof include 1- pyrrolidinyl, piperidino, 1-piperazinyl, morpholino,
- alkoxycarbonyl examples include Ci-6 alkoxy-carbonyl wherein the alkoxy moiety is C 1 -6 alkoxy. Examples thereof include methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, sec- butoxycarbonyl, tert-butoxycarbonyl, pentyloxycarbonyl,
- alkoxycarbonylamino examples include Ci-6 alkoxy- carbonylamino wherein the alkoxy moiety is Ci-6 alkoxy. Examples thereof include methoxycarbonylamino, ethoxycarbonylamino, propoxycarbonylamino, isopropoxycarbonylamino,
- alkylcarbonyl examples include Ci-6 alkyl-carbonyl wherein the alkyl moiety is Ci-6 alkyl. Examples thereof include acetyl, ethylcarbonyl, propylcarbonyl, isopropylcarbonyl, butylcarbonyl, isobutylcarbonyl, sec-butylcarbonyl, tert- butylcarbonyl, pentylcarbonyl, hexylcarbonyl, etc.
- cycloalkyloxy examples include C3-8 cycloalkyloxy such as cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, cycloheptyloxy, cyclooctyloxy, etc.
- cycloalkylcarbonyl examples include C3-8 cycloalkyl- carbonyl such as cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, cycloheptylcarbonyl, cyclooctylcarbonyl, etc.
- heterocyclylcarbonyl group include a 5- to 10-membered
- heterocyclyl (preferably 1 to 3, more preferably 1 or 2) heteroatoms selected from a nitrogen atom, an oxygen atom and a sulfur atom.
- heterocyclyl moiety are same as the examples of the 5- to 10-membered aromatic heterocyclic group mentioned above.
- heterocyclylcarbonyl group include pyridylcarbonyl (e.g., 2- pyridylcarbonyl, 3-pyridylcarbonyl, 4-pyridylcarbonyl) .
- arylsulfonyl examples include Ce-14 (preferably C6-10) arylsulfonyl such as phenylsulfonyl, naphthylsulfonyl (e.g., 1- naphthylsulfonyl, 2-naphthylsulfonyl) , etc. Preferable examples thereof include phenylsulfonyl .
- cycloalkylalkylsulfonyl examples include C3-8
- cycloalkyl-Ci-6 alkylsulfonyl such as cyclopropylmethylsulfonyl, cyclobutylmethylsulfonyl, cyclopentylmethylsulfonyl,
- heterocyclylsulfonyl group include a 5- to 10-membered
- heterocyclyl (preferably 1 to 3, more preferably 1 or 2) heteroatoms selected from a nitrogen atom, an oxygen atom and a sulfur atom.
- heterocyclyl moiety are same as the examples of the 5- to 10-membered aromatic heterocyclic group mentioned above.
- heterocyclylsulfonyl group include imidazolylsulfonyl .
- alkylsulfonyl examples include Ci_6 alkylsulfonyl wherein the alkyl moiety is Ci_6 alkyl. Examples thereof include methylsulfonyl, ethylsulfonyl, propylsulfonyl,
- cyclopropyl optionally substituted by 1 to 3 halogen atoms examples include cyclopropyl optionally substituted by 1 fluorine atom such as cyclopropyl, 2-fluorocyclopropyl, etc.
- phenyl optionally substituted by 1 to 3 halogen atoms include phenyl substituted by two fluorine atoms such as 2, 4-difluorophenyl, etc.
- Examples of "5- to 10-membered saturated heterocyclic group” include a 5- to 10-membered (preferably 5- or 6-membered) saturated heterocyclic group containing 1 to 4 (preferably 1 to 3, more preferably 1 or 2) heteroatoms selected from a nitrogen atom, an oxygen atom and a sulfur atom. Examples thereof include pyrrolidinyl , piperidyl, piperazinyl, morpholinyl,
- Examples of "6-membered ring optionally substituted by amino or oxo" formed by R 34 and R 35 include a 6-membered ring optionally containing one nitrogen atom, and said ring is optionally substituted by amino or oxo. Examples thereof include cyclohexene and dihydropyridine, each optionally substituted by amino or oxo.
- Examples of "5- or 6-membered ring optionally substituted by alkyl" formed by R 1 and R 2 include a 5- or 6-membered
- R 1 and R 2 are optionally bonded to form -0-C3 ⁇ 4-CH (C3 ⁇ 4) - wherein the oxygen atom is bonded to the phenyl ring of the quinolone ring as shown below.
- Examples of "5- or 6-membered ring optionally substituted by oxo" formed by R 4 and R 5 include a 5- or 6-membered
- Examples of "5- or 6-membered ring optionally substituted by alkyl or oxo" formed by R 10 and R 11 include a 5- or 6-membered (preferably 5-membered) ring containing 2 or 3 nitrogen atoms, and said ring is optionally substituted by alkyl or oxo.
- R 12 and R 13 are optionally bonded to form -(C3 ⁇ 4)4- as shown below.
- X is a hydrogen atom or a fluorine atom, preferably, a fluorine atom.
- R is a hydrogen atom or alkyl, preferably, a hydrogen atom.
- R 1 is (1) cyclopropyl optionally substituted by 1 to 3 halogen atoms or (2) phenyl optionally substituted by 1 to 3 halogen atoms, preferably, cyclopropyl, 2-fluorocyclopropyl or 2 , 4-difluorophenyl .
- R 2 is a hydrogen atom; alkyl optionally substituted by 1 or 2 substituents selected from the group consisting of a halogen atom and hydroxyl; alkoxy; haloalkoxy; a halogen atom; cyano; cyclopropyl; nitro; amino; formyl; alkenyl or alkynyl, preferably, alkyl, alkoxy, haloalkoxy, a chlorine atom or cyano, more preferably, Ci-6 alkyl, Ci-6 alkoxy, Ci-6 alkoxy substituted by 1 to 3 halogen atoms, a chlorine atom or cyano, still more preferably, methyl, methoxy or a chlorine atom.
- Examples of a fused heterocyclic group of the formula (A) or B) include a fused heterocyclic group of the formula
- heterocyclic group is optionally substituted by 1 or 2
- substituents selected from the group consisting of a halogen atom, cyano, nitro, hydroxy and alkyl.
- fused heterocyclic group of the formula (A) or (B) include a fused heterocyclic group of the formula
- heterocyclic group is optionally substituted by 1 or 2
- substituents selected from the group consisting of a halogen atom, cyano, nitro, hydroxy and alkyl.
- fused heterocyclic group of the formula (A) or (B) include a fused heterocyclic group of the
- heterocyclic group is optionally substituted by 1 or 2
- substituents selected from the group consisting of a halogen atom, cyano, nitro, hydroxy and alkyl.
- Examples of a group of the formula (C) include a group of the formula
- Preferable examples of a group of the formula (C) include a roup of the formula
- R , R and R are as defined above.
- R 6 , R 7 and R 8 are each
- alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of a halogen atom and amino,
- alkyl optionally substituted by alkyl .
- Examples of a group of the formula (D) or (E) include a roup of the formula
- R is as defined above.
- R is preferably a hydrogen atom, a halogen atom, nitro or amino.
- R is 3-pyridyl optionally substituted by 1 substituents selected from the group consisting of
- alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of a halogen atom, alkylamino, dialkylamino and hydroxy,
- a cyclic amino group e.g., 1-piperazinyl
- R 3 is a group of the formula
- alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of a halogen atom, alkylamino, dialkylamino and hydroxy,
- R is N
- R is 5-pyrimidinyl substituted by 1 or 2 substituents selected from the group consisting of amino, alkylamino and dialkylamino .
- R is 2-indolyl, 3-indolyl, 5-indolyl or 6- indolyl, each optionally substituted by 1 or 2 substituents selected from the group consisting of
- alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of amino, alkoxycarbonylamino, alkylamino and dialkylamino,
- heterocyclylcarbonyl group e.g, pyridylcarbonyl
- alkyl optionally substituted by 1 to 3 halogen atoms
- heterocyclylsulfonyl group e.g.,
- imidazolylsulfonyl optionally substituted by 1 to 3 alkyl
- R 3 is 2-indolyl optionally substitutedr 2 substituents selected from the group consisting of
- alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of amino, alkoxycarbonylamino, alkylamino and dialkylamino,
- heterocyclylcarbonyl group e.g, pyridylcarbonyl
- alkyl optionally substituted by 1 to 3 halogen atoms
- cycloalkylalkylsulfonyl optionally substituted by 1 to 3 substituents selected from the group consisting of alkyl and oxo (e.g.,
- heterocyclylsulfonyl group e.g.,
- imidazolylsulfonyl optionally substituted by 1 to 3 alkyl
- Examples of a group of the formula (F) or (G) include a group of the formula
- Examples of a group of the formula (K) include a group the formula
- R 10 , R 11 , R 12 , R 13 , R 14 and R 15 are as defined above.
- R 31 is a hydrogen atom or alkyl.
- More preferable examples of a group of the formula (K) include a group of the formula
- R lla , R 1Ja and R 15a are each independently,
- R 10a and R lla are optionally bonded to form a 5- or 6-membered ring optionally substituted by alkyl or oxo,
- R 10a , R lla , R 13a and R 15a are not simultaneously hydrogen atom. ly, R is a group of the formula
- alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of cyano, alkylamino and dialkylamino,
- benzimidazolyl triazolyl
- alkyl optionally substituted by alkyl, alkoxycarbonyl, carboxy or phenyl.
- R 3 is a group of the formula
- R a is (a) alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of cyano, alkylamino and dialkylamino,
- R is a group of the formula
- R 18 is alkyl optionally substituted by 1 to 3 substituents selected from the group consisting of a halogen atom and phenyl, and
- R 19 and R 20 are each independently,
- a cyclic amino group e.g., 1-piperazinyl
- alkyl optionally substituted by alkyl
- alkylcarbonyl optionally substituted by a cyclic amino group e.g., morpholino
- R 3 is a group of the formula
- R 18a is alkyl
- R 19a is (a) a halogen atom
- a cyclic amino group e.g., 1-piperazinyl
- alkyl optionally substituted by alkyl
- alkylcarbonyl optionally substituted by a cyclic amino group (e.g., morpholino)
- alkylsulfonyl and
- (k) -CH N-OR 21 wherein R 21 is a hydrogen atom or alkyl optionally substituted by alkylamino or dialkylamino .
- R is a hydrogen atom
- R 1 is cyclopropyl, 2-fluorocyclopropyl or 2 , 4-difluorophenyl ;
- R 2 is Ci-6 alkyl (e.g., methyl), Ci-6 alkoxy (e.g., methoxy) or chlorine atom; or
- R 1 and R 2 are optionally bonded to form -O-CH2-CH (C3 ⁇ 4) - wherein the oxygen atom is bonded to the phenyl ring of the quinolone ring;
- R 3 is a fused heterocyclic group of the formula
- X 1 is C (R 5 ) or N
- R 4 is a hydrogen atom or Ci-6 alkyl
- R 5 is (a) a hydrogen atom
- Ci-6 alkyl optionally substituted by 1 to 3 halogen atoms ,
- Ci-6 alkoxy optionally substituted by 1 to 3 halogen atoms
- said fused heterocyclic group is optionally substituted by 1 or 2 substituents selected from the group consisting of a halogen atom, cyano, nitro, hydroxy and Ci-6 alkyl,
- R is a hydrogen atom
- R 1 is cyclopropyl, 2-fluorocyclopropyl or 2 , 4-difluorophenyl ;
- R 2 is Ci-6 alkyl (e.g., methyl), Ci-6 alkoxy (e.g., methoxy) or a chlorine atom; or
- R 1 and R 2 are optionally bonded to form -0-CH 2 -CH (CH 3 ) - wherein the oxygen atom is bonded to the phenyl ring of the quinolone ring;
- X 2 is C (R 8 ) or N
- R 6 , R 7 and R 8 are each independently,
- Ci-6 alkyl optionally substituted by 1 to 3
- R is a hydrogen atom
- R 1 is cyclopropyl, 2-fluorocyclopropyl or 2 , 4-difluorophenyl ;
- R 2 is Ci-6 alkyl (e.g., methyl), Ci-6 alkoxy (e.g., methoxy) or a chlorine atom;
- R >3 is a group of the formula
- X 3 and X 4 are N, or
- X 3 is N and X 4 is CH, or
- X 3 is CH and X 4 is N
- R 6 is a hydrogen atom, a halogen atom, nitro or amino
- R is a hydrogen atom
- R 1 is cyclopropyl, 2-fluorocyclopropyl or 2 , 4-difluorophenyl ;
- R 2 is Ci-6 alkyl (e.g., methyl), Ci_ 6 alkoxy (e.g., methoxy) or a chlorine atom; and
- R 3 is a group of the formula
- R is a hydrogen atom
- R 1 is cyclopropyl, 2-fluorocyclopropyl or 2 , 4-difluorophenyl ;
- R 2 is Ci-6 alkyl (e.g., methyl), Ci-6 alkoxy (e.g., methoxy) or a chlorine atom; or
- R 1 and R 2 are optionally bonded to form -O-CH2-CH (CH 3 ) - wherein the oxygen atom is bonded to the phenyl ring of the quinolone ring;
- R 3 is a group of the formula
- Ci-6 alkyl optionally substituted by 1 to 3
- R is a hydrogen atom
- R 1 is cyclopropyl, 2-fluorocyclopropyl or 2 , 4-difluorophenyl ;
- R 2 is Ci-6 alkyl (e.g., methyl), Ci-6 alkoxy (e.g., methoxy) or a chlorine atom; or
- R 1 and R 2 are optionally bonded to form -O-CH2-CH (CH 3 ) - wherein the oxygen atom is bonded to the phenyl ring of the quinolone ring;
- R 3 is a group of the formula
- R 22 is (a) cyano
- R is a hydrogen atom
- R 1 is cyclopropyl, 2-fluorocyclopropyl or 2 , 4-difluorophenyl ;
- R 2 is Ci-6 alkyl (e.g., methyl), Ci_ 6 alkoxy (e.g., methoxy) or a chlorine atom; and
- R 3 is 5-pyrimidinyl substituted by 1 or 2 substituents selected from the group consisting of amino, Ci_6 alkylamino and di ( Ci_6 alkyl) amino,
- R is a hydrogen atom
- R 1 is cyclopropyl, 2-fluorocyclopropyl or 2 , 4-difluorophenyl ;
- R 2 is Ci-6 alkyl (e.g., methyl), Ci-6 alkoxy (e.g., methoxy) or a chlorine atom;
- R 3 is 2-indolyl optionally substituted by 1 or 2 substituents selected from the group consisting of
- Ci-6 alkyl optionally substituted by 1 to 3
- Ci-6 alkyl-carbonyl optionally substituted by a substituent selected from the group consisting of
- heterocyclylcarbonyl group e.g., pyridylcarbonyl
- Ci-6 alkyl optionally substituted by 1 to 3 halogen atoms
- heterocyclylsulfonyl group e.g.,
- imidazolylsulfonyl optionally substituted by 1 to 3 Ci-6 alkyl, and
- R is a hydrogen atom
- R 1 is cyclopropyl, 2-fluorocyclopropyl or 2 , 4-difluorophen
- R 2 is Ci-6 alkyl (e.g., methyl), Ci-6 alkoxy (e.g., methoxy) chlorine atom;
- R 3 is a group of the formula
- R is a hydrogen atom or Ci-6 alkyl
- R 24 , R 25 , R 26 and R 27 are each independently,
- R is a hydrogen atom
- R 1 is cyclopropyl, 2-fluorocyclopropyl or 2 , 4-difluorophenyl ;
- R 2 is Ci-6 alkyl (e.g., methyl), Ci-6 alkoxy (e.g., methoxy) or chlorine atom; and
- R 3 is a group of the formula
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (33)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NO12827305A NO2751083T3 (en) | 2011-08-31 | 2012-08-30 | |
DK12827305.9T DK2751083T3 (en) | 2011-08-31 | 2012-08-30 | Quinolone compound |
ES12827305.9T ES2660973T3 (en) | 2011-08-31 | 2012-08-30 | Quinolone compound |
BR112014000665A BR112014000665B8 (en) | 2011-08-31 | 2012-08-30 | compound, pharmaceutical composition, antimicrobial agent, and, use of a compound |
KR1020147017145A KR101996697B1 (en) | 2011-08-31 | 2012-08-30 | Quinolone compound |
KR1020147031410A KR20140139132A (en) | 2011-08-31 | 2012-08-30 | Quinolone compound |
SI201231233T SI2751083T1 (en) | 2011-08-31 | 2012-08-30 | Quinolone compound |
KR1020137018036A KR101560073B1 (en) | 2011-08-31 | 2012-08-30 | Quinolone compound |
SG2014004162A SG2014004162A (en) | 2011-08-31 | 2012-08-30 | Quinolone compound |
CA2845459A CA2845459C (en) | 2011-08-31 | 2012-08-30 | Quinolone compound and antimicrobial use thereof |
PL12827305T PL2751083T3 (en) | 2011-08-31 | 2012-08-30 | Quinolone compound |
JP2014527483A JP6106174B2 (en) | 2011-08-31 | 2012-08-30 | Quinolone compounds |
CN201280041352.0A CN103764631B (en) | 2011-08-31 | 2012-08-30 | Quinolone compound |
EA201490530A EA030867B1 (en) | 2011-08-31 | 2012-08-30 | Quinolone derivative |
EP17202139.6A EP3318557A3 (en) | 2011-08-31 | 2012-08-30 | Quinolone compound |
LTEP12827305.9T LT2751083T (en) | 2011-08-31 | 2012-08-30 | Quinolone compound |
NZ620447A NZ620447B2 (en) | 2011-08-31 | 2012-08-30 | Quinolone compound |
AU2012303954A AU2012303954B2 (en) | 2011-08-31 | 2012-08-30 | Quinolone compound |
MX2014002338A MX371361B (en) | 2011-08-31 | 2012-08-30 | Quinolone compound. |
EP12827305.9A EP2751083B1 (en) | 2011-08-31 | 2012-08-30 | Quinolone compound |
IL230559A IL230559B (en) | 2011-08-31 | 2014-01-20 | Quinolone compound |
US14/193,656 US9067887B2 (en) | 2011-08-31 | 2014-02-28 | Quinolone compound |
ZA2014/02326A ZA201402326B (en) | 2011-08-31 | 2014-03-28 | Quinolone compound |
HK14112301.3A HK1198828A1 (en) | 2011-08-31 | 2014-12-08 | Quinolone compound |
US14/709,261 US9440951B2 (en) | 2011-08-31 | 2015-05-11 | Quinolone compound |
US15/225,130 US20160340314A1 (en) | 2011-08-31 | 2016-08-01 | Quinolone compound |
AU2017203756A AU2017203756B2 (en) | 2011-08-31 | 2017-06-02 | Quinolone compound |
US15/691,216 US20170362180A1 (en) | 2011-08-31 | 2017-08-30 | Quinolone compound |
CY20181100309T CY1120066T1 (en) | 2011-08-31 | 2018-03-14 | KINOLON UNION |
HRP20180483TT HRP20180483T1 (en) | 2011-08-31 | 2018-03-22 | Quinolone compound |
US16/185,437 US20190077762A1 (en) | 2011-08-31 | 2018-11-09 | Quinolone compound |
US16/659,987 US20200055823A1 (en) | 2011-08-31 | 2019-10-22 | Quinolone compound |
US17/073,513 US20210032207A1 (en) | 2011-08-31 | 2020-10-19 | Quinolone compound |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011001477 | 2011-08-31 | ||
CNPCT/CN2011/001477 | 2011-08-31 | ||
CNPCT/CN2012/001044 | 2012-08-06 | ||
CN2012001044 | 2012-08-06 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/193,656 Continuation US9067887B2 (en) | 2011-08-31 | 2014-02-28 | Quinolone compound |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013029548A1 true WO2013029548A1 (en) | 2013-03-07 |
Family
ID=47755336
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2012/080753 WO2013029548A1 (en) | 2011-08-31 | 2012-08-30 | Quinolone compound |
Country Status (29)
Country | Link |
---|---|
US (7) | US9067887B2 (en) |
EP (2) | EP3318557A3 (en) |
JP (4) | JP6106174B2 (en) |
KR (3) | KR101996697B1 (en) |
CN (3) | CN105712976A (en) |
AR (1) | AR087747A1 (en) |
AU (2) | AU2012303954B2 (en) |
BR (1) | BR112014000665B8 (en) |
CA (1) | CA2845459C (en) |
CO (1) | CO6920292A2 (en) |
CY (1) | CY1120066T1 (en) |
DK (1) | DK2751083T3 (en) |
EA (2) | EA034787B1 (en) |
ES (1) | ES2660973T3 (en) |
HK (4) | HK1198828A1 (en) |
HR (1) | HRP20180483T1 (en) |
HU (1) | HUE036301T2 (en) |
IL (1) | IL230559B (en) |
LT (1) | LT2751083T (en) |
MX (2) | MX371361B (en) |
MY (1) | MY165004A (en) |
NO (1) | NO2751083T3 (en) |
PL (1) | PL2751083T3 (en) |
PT (1) | PT2751083T (en) |
SG (3) | SG2014004162A (en) |
SI (1) | SI2751083T1 (en) |
TW (3) | TWI583680B (en) |
WO (1) | WO2013029548A1 (en) |
ZA (1) | ZA201402326B (en) |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014178008A1 (en) | 2013-05-02 | 2014-11-06 | Actelion Pharmaceuticals Ltd | Quinolone derivatives |
WO2015050989A2 (en) | 2013-10-01 | 2015-04-09 | Cs Therapeutics Inc. | Macrocyclic compounds for the treatment of proliferative diseases |
US9227985B2 (en) | 2013-03-15 | 2016-01-05 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
US9290514B2 (en) | 2013-07-08 | 2016-03-22 | Incyte Holdings Corporation | Tricyclic heterocycles as BET protein inhibitors |
US9309246B2 (en) | 2013-12-19 | 2016-04-12 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
US9315501B2 (en) | 2013-11-26 | 2016-04-19 | Incyte Corporation | Bicyclic heterocycles as BET protein inhibitors |
US9399640B2 (en) | 2013-11-26 | 2016-07-26 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
US9527864B2 (en) | 2014-09-15 | 2016-12-27 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
US9540368B2 (en) | 2014-04-23 | 2017-01-10 | Incyte Corporation | 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins |
WO2017017631A3 (en) * | 2015-07-28 | 2017-04-06 | Vyome Biosciences Pvt. Ltd. | Antibacterial therapeutics and prophylactics |
US10189832B2 (en) | 2016-06-20 | 2019-01-29 | Incyte Corporation | Crystalline solid forms of a BET inhibitor |
US10314820B2 (en) | 2014-12-04 | 2019-06-11 | Procomcure Biotech Gmbh | Imidazole-based heterocyclic compounds |
US10322110B2 (en) | 2014-12-04 | 2019-06-18 | Procomcure Biotech Gmbh | Imidazole-based antimicrobial agents |
US10329305B2 (en) | 2015-10-29 | 2019-06-25 | Incyte Corporation | Amorphous solid form of a BET protein inhibitor |
WO2020036154A1 (en) | 2018-08-13 | 2020-02-20 | Otsuka Pharmaceutical Co., Ltd. | Novel medicament for treating inflammatory bowel disease |
WO2020163816A1 (en) * | 2019-02-08 | 2020-08-13 | Frequency Therapeutics, Inc. | Quinolin-4-one and 4(1h)-cinnolinone compounds and methods of using same |
WO2021161981A1 (en) | 2020-02-10 | 2021-08-19 | Otsuka Pharmaceutical Co., Ltd. | Novel medicament for treating hepatic encephalopathy |
WO2021161982A1 (en) | 2020-02-10 | 2021-08-19 | Otsuka Pharmaceutical Co., Ltd. | Novel modifying reagents for the presence ratio of intestinal microflora |
WO2021161983A1 (en) | 2020-02-10 | 2021-08-19 | Otsuka Pharmaceutical Co., Ltd. | Novel medicament for treating inflammatory disease |
WO2023208172A1 (en) * | 2022-04-29 | 2023-11-02 | Beigene , Ltd. | Substituted 7- (pyrimidin-4-yl) quinolin-4 (1h) -one compounds as cyclin dependent kinase inhibitors |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
WO2024012421A1 (en) * | 2022-07-11 | 2024-01-18 | Otsuka Pharmaceutical Co., Ltd. | Pharmaceutical compositions comprising a quinolone compound for irritable bowel syndrome |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3312176A1 (en) * | 2011-02-01 | 2018-04-25 | Emergent Product Development Gaithersburg Inc. | Antimicrobial 4-oxoquinolizines |
TWI583680B (en) * | 2011-08-31 | 2017-05-21 | 大塚製藥股份有限公司 | Quinolone compound |
US10226464B2 (en) * | 2015-12-29 | 2019-03-12 | ImmuneTarget, Inc. | Small molecule NF-κB inhibitors |
US11352328B2 (en) | 2016-07-12 | 2022-06-07 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus |
KR102537749B1 (en) | 2017-06-14 | 2023-05-26 | 산요 시키소 가부시키가이샤 | Pigment dispersant and colored composition including the same |
CN107964020B (en) * | 2018-01-11 | 2019-07-05 | 河南大学 | Fluoro- 7- piperazine nalidixic acid compound of 1- (N- lavo-ofloxacin amide groups) -6- and its preparation method and application |
CN108191889B (en) * | 2018-01-11 | 2019-06-07 | 河南大学 | Fluoro- 7- piperazine nalidixic acid compound of 1- (N- Ofloxacin amide groups) -6- and its preparation method and application |
CN110563645B (en) * | 2019-06-14 | 2021-03-30 | 山东省联合农药工业有限公司 | Quinolone compound and preparation method and application thereof |
CN112624970B (en) * | 2019-09-24 | 2022-10-28 | 南开大学 | Application of 8-bit aryl substituted quinoline nitrogen oxide in plant virus resistance and sterilization |
CN112870196B (en) * | 2019-11-11 | 2022-02-18 | 山东畜牧兽医职业学院 | Composition for treating drug-resistant microbial bacteria |
WO2024128235A1 (en) * | 2022-12-13 | 2024-06-20 | 大塚製薬株式会社 | Method for producing quinolone compound |
WO2024138292A1 (en) * | 2022-12-26 | 2024-07-04 | 深圳阿尔法分子科技有限责任公司 | Novel phenylquinolone compound having antibacterial and anticancer functions, and preparation thereof |
CN118255716A (en) * | 2022-12-26 | 2024-06-28 | 深圳阿尔法分子科技有限责任公司 | Novel phenyl quinolone compound with antibacterial and anticancer functions and preparation thereof |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4797490A (en) * | 1984-12-06 | 1989-01-10 | Pfizer Inc. | Process for the preparation of 3-(2'-fluorophenyl)pyridine |
EP0343398A2 (en) * | 1988-05-11 | 1989-11-29 | Bayer Ag | 7-Substituted quinolone- and naphthyridinecarboxylic acid derivatives |
JPH0366301B2 (en) | 1984-12-06 | 1991-10-16 | Pfizer | |
WO1999003465A1 (en) | 1997-07-16 | 1999-01-28 | Eisai Co., Ltd. | Antibiotics containing indole derivatives |
WO1999007682A1 (en) | 1997-08-08 | 1999-02-18 | Toyama Chemical Co., Ltd. | Quinolonecarboxylic acid derivatives or salts thereof |
WO1999051588A1 (en) | 1998-04-06 | 1999-10-14 | Toyama Chemical Co., Ltd. | Quinolonecarboxylic acid derivatives or salts thereof |
EP1160241A2 (en) * | 2000-06-03 | 2001-12-05 | CPC Cellular Process Chemistry Systems GmbH | Process for the preparation of quinolon-3-carboxylic acids |
EP2177214A1 (en) | 2008-10-17 | 2010-04-21 | Ferrer Internacional, S.A. | Solid Oral Dosage Forms and Uses |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5781486A (en) * | 1980-11-10 | 1982-05-21 | Otsuka Pharmaceut Co Ltd | Benzo(ij)quinolidine-2-carboxylic acid derivative |
JPS5872589A (en) * | 1981-10-28 | 1983-04-30 | Dai Ichi Seiyaku Co Ltd | Pyrido(1,2,3-de)(1,4)benzoxazine derivative |
US4443447A (en) | 1982-10-25 | 1984-04-17 | Riker Laboratories, Inc. | Phenyl-substituted tricyclic antibacterial agents |
US4623650A (en) * | 1984-12-06 | 1986-11-18 | Pfizer Inc. | Antibiotic derivatives of 7-phenyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids |
US4636506A (en) * | 1984-12-06 | 1987-01-13 | Pfizer, Inc. | 7-heterocyclic-1,4-dihydroquinolones |
JPS62228063A (en) * | 1985-12-27 | 1987-10-06 | Sankyo Co Ltd | Quinolinecarboxylic acid derivative |
IT1197841B (en) * | 1986-10-14 | 1988-12-06 | Mediolanum Farmaceutici Srl | PYRID-BENZOTHIAZINIC DERIVATIVES WITH ANTIBACTERIAL ACTIVITY AND LONG LIFE |
US4929613A (en) | 1987-08-26 | 1990-05-29 | Warner-Lambert Company | Antibacterial agents |
US5081254A (en) | 1987-08-26 | 1992-01-14 | Warner-Lambert Company | Antibacterial agents |
US5075319A (en) * | 1987-09-08 | 1991-12-24 | Sterling Drug Inc. | Pyridinyl-quinolone compounds, their preparation and use |
US4839355A (en) * | 1987-09-09 | 1989-06-13 | Sterling Drug Inc. | Tricyclic-pyridinylquinoline compounds, their preparation and use |
WO1989005643A1 (en) * | 1987-12-18 | 1989-06-29 | Pfizer Inc. | Heterocyclic-substituted quinoline-carboxylic acids |
JPH0366301A (en) | 1989-08-03 | 1991-03-22 | Asahi Corp | Sole injection molding metal mold |
KR910009333B1 (en) * | 1989-10-23 | 1991-11-11 | 재단법인 한국화학연구소 | Antimicrobial quinoline compounds and the preparation process thereof |
JP2613139B2 (en) * | 1990-07-19 | 1997-05-21 | エスエス製薬 株式会社 | Quinolonecarboxylic acid derivatives |
US5308843A (en) * | 1990-09-11 | 1994-05-03 | Sterling Drug Inc. | Method of inhibiting mammalian topoisomerase II and malignant cell growth in mammals, with substituted (S)-3-methyl-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4 ]-benzoxazine(and-benzothiazine)-6-carboxylic acids |
ZA919601B (en) | 1990-12-05 | 1992-10-28 | Synphar Lab Inc | 7-substituted-6-fluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid compounds useful as antibacterial agents |
ATE245638T1 (en) * | 1994-08-12 | 2003-08-15 | Toyama Chemical Co Ltd | NEW QUINOLONE OR NAPHTHYRIDONE CARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF |
DE69802692D1 (en) | 1997-06-26 | 2002-01-10 | Dong Wha Pharm Ind Co Ltd | DERIVATIVES OF CHINOLONIC CARBONIC ACID |
KR100611869B1 (en) | 1997-10-27 | 2006-08-11 | 도야마 가가쿠 고교 가부시키가이샤 | Processes for producing 7-isoindolinequinolonecarboxylic derivatives and intermediates thereof, salts of 7-isoindolinequinolonecarboxylic acids, hydrates thereof, and composition containing the same as active ingredient |
JP2000229946A (en) * | 1998-12-10 | 2000-08-22 | Toyama Chem Co Ltd | Production of quinolonecarboxylic acid and its intermediate |
WO2000046223A1 (en) * | 1999-02-05 | 2000-08-10 | Toyama Chemical Co., Ltd. | Tricyclic quinolonecarboxylic acid derivatives or salts thereof |
US20020049223A1 (en) * | 1999-11-05 | 2002-04-25 | Elmore Steven W. | Quinoline and naphthyridine carboxylic acid antibacterials |
AU2001280091A1 (en) * | 2000-08-01 | 2002-02-13 | Wockhardt Limited | Inhibitors of cellular efflux pumps of microbes |
JP2003104988A (en) * | 2001-09-28 | 2003-04-09 | Sato Pharmaceutical Co Ltd | Quinolone derivative useful as antibacterial agent |
US7012144B2 (en) | 2001-12-31 | 2006-03-14 | Korea Research Institute Of Chemical Technology | Quinolone carboxylic acid derivatives |
JP3885679B2 (en) * | 2002-06-28 | 2007-02-21 | 株式会社日立製作所 | Electronics |
US20070224282A1 (en) * | 2005-03-28 | 2007-09-27 | Toyama Chemical Co., Ltd. | Fine Dispersion of Sparingly Soluble Drug and Process for Producing the Same |
JP4127847B2 (en) * | 2006-02-17 | 2008-07-30 | 国立大学法人九州大学 | Microorganism detection method and microorganism detection kit |
CN101168541A (en) * | 2006-10-26 | 2008-04-30 | 孙飘扬 | Quinolone carboxylic acid derivatives, preparation method and medical use thereof |
US8124623B2 (en) * | 2006-11-10 | 2012-02-28 | Actelion Pharmaceuticals Ltd. | 5-hydroxymethyl-oxazolidin-2-one-derivatives and their uses as antibacterials |
US20090270379A1 (en) * | 2008-04-23 | 2009-10-29 | Macielag Mark J | Quinolone derivatives useful as antibacterial agents |
TWI583680B (en) * | 2011-08-31 | 2017-05-21 | 大塚製藥股份有限公司 | Quinolone compound |
-
2012
- 2012-08-30 TW TW105116079A patent/TWI583680B/en active
- 2012-08-30 WO PCT/CN2012/080753 patent/WO2013029548A1/en active Application Filing
- 2012-08-30 KR KR1020147017145A patent/KR101996697B1/en active IP Right Grant
- 2012-08-30 CN CN201610052007.7A patent/CN105712976A/en active Pending
- 2012-08-30 JP JP2014527483A patent/JP6106174B2/en active Active
- 2012-08-30 TW TW106102905A patent/TW201718506A/en unknown
- 2012-08-30 ES ES12827305.9T patent/ES2660973T3/en active Active
- 2012-08-30 AR ARP120103215A patent/AR087747A1/en unknown
- 2012-08-30 MX MX2014002338A patent/MX371361B/en active IP Right Grant
- 2012-08-30 SG SG2014004162A patent/SG2014004162A/en unknown
- 2012-08-30 MY MYPI2014000509A patent/MY165004A/en unknown
- 2012-08-30 EP EP17202139.6A patent/EP3318557A3/en not_active Withdrawn
- 2012-08-30 EP EP12827305.9A patent/EP2751083B1/en active Active
- 2012-08-30 SG SG10201606932TA patent/SG10201606932TA/en unknown
- 2012-08-30 EA EA201890098A patent/EA034787B1/en not_active IP Right Cessation
- 2012-08-30 PL PL12827305T patent/PL2751083T3/en unknown
- 2012-08-30 SI SI201231233T patent/SI2751083T1/en unknown
- 2012-08-30 LT LTEP12827305.9T patent/LT2751083T/en unknown
- 2012-08-30 TW TW101131516A patent/TWI606044B/en active
- 2012-08-30 CA CA2845459A patent/CA2845459C/en active Active
- 2012-08-30 DK DK12827305.9T patent/DK2751083T3/en active
- 2012-08-30 KR KR1020137018036A patent/KR101560073B1/en active IP Right Grant
- 2012-08-30 KR KR1020147031410A patent/KR20140139132A/en not_active Application Discontinuation
- 2012-08-30 BR BR112014000665A patent/BR112014000665B8/en not_active IP Right Cessation
- 2012-08-30 PT PT128273059T patent/PT2751083T/en unknown
- 2012-08-30 SG SG10201505811QA patent/SG10201505811QA/en unknown
- 2012-08-30 CN CN201510404261.4A patent/CN105017151B/en active Active
- 2012-08-30 AU AU2012303954A patent/AU2012303954B2/en active Active
- 2012-08-30 HU HUE12827305A patent/HUE036301T2/en unknown
- 2012-08-30 NO NO12827305A patent/NO2751083T3/no unknown
- 2012-08-30 EA EA201490530A patent/EA030867B1/en not_active IP Right Cessation
- 2012-08-30 CN CN201280041352.0A patent/CN103764631B/en active Active
-
2014
- 2014-01-20 IL IL230559A patent/IL230559B/en active IP Right Grant
- 2014-02-27 MX MX2019010100A patent/MX2019010100A/en unknown
- 2014-02-28 US US14/193,656 patent/US9067887B2/en not_active Expired - Fee Related
- 2014-03-27 CO CO14065672A patent/CO6920292A2/en active IP Right Grant
- 2014-03-28 ZA ZA2014/02326A patent/ZA201402326B/en unknown
- 2014-12-08 HK HK14112301.3A patent/HK1198828A1/en not_active IP Right Cessation
-
2015
- 2015-05-11 US US14/709,261 patent/US9440951B2/en active Active
- 2015-08-28 JP JP2015168524A patent/JP6039025B2/en active Active
-
2016
- 2016-04-19 HK HK16104451.6A patent/HK1216528A1/en unknown
- 2016-08-01 US US15/225,130 patent/US20160340314A1/en not_active Abandoned
- 2016-09-16 JP JP2016181129A patent/JP2017039733A/en active Pending
- 2016-12-22 HK HK16114584A patent/HK1226077A1/en unknown
-
2017
- 2017-06-02 AU AU2017203756A patent/AU2017203756B2/en active Active
- 2017-08-30 US US15/691,216 patent/US20170362180A1/en not_active Abandoned
-
2018
- 2018-03-14 CY CY20181100309T patent/CY1120066T1/en unknown
- 2018-03-22 HR HRP20180483TT patent/HRP20180483T1/en unknown
- 2018-04-27 JP JP2018087535A patent/JP2018150324A/en active Pending
- 2018-09-12 HK HK18111686.6A patent/HK1252389A1/en unknown
- 2018-11-09 US US16/185,437 patent/US20190077762A1/en not_active Abandoned
-
2019
- 2019-10-22 US US16/659,987 patent/US20200055823A1/en not_active Abandoned
-
2020
- 2020-10-19 US US17/073,513 patent/US20210032207A1/en not_active Abandoned
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4797490A (en) * | 1984-12-06 | 1989-01-10 | Pfizer Inc. | Process for the preparation of 3-(2'-fluorophenyl)pyridine |
JPH0366301B2 (en) | 1984-12-06 | 1991-10-16 | Pfizer | |
EP0343398A2 (en) * | 1988-05-11 | 1989-11-29 | Bayer Ag | 7-Substituted quinolone- and naphthyridinecarboxylic acid derivatives |
JPH01319463A (en) | 1988-05-11 | 1989-12-25 | Bayer Ag | 7-substituted quinolone and naphrhylicone- carboxylic acid derivative |
WO1999003465A1 (en) | 1997-07-16 | 1999-01-28 | Eisai Co., Ltd. | Antibiotics containing indole derivatives |
WO1999007682A1 (en) | 1997-08-08 | 1999-02-18 | Toyama Chemical Co., Ltd. | Quinolonecarboxylic acid derivatives or salts thereof |
WO1999051588A1 (en) | 1998-04-06 | 1999-10-14 | Toyama Chemical Co., Ltd. | Quinolonecarboxylic acid derivatives or salts thereof |
CN1299356A (en) * | 1998-04-06 | 2001-06-13 | 富山化学工业株式会社 | Quinolonecarboxylic acid derivatives or salts thereof |
EP1160241A2 (en) * | 2000-06-03 | 2001-12-05 | CPC Cellular Process Chemistry Systems GmbH | Process for the preparation of quinolon-3-carboxylic acids |
EP2177214A1 (en) | 2008-10-17 | 2010-04-21 | Ferrer Internacional, S.A. | Solid Oral Dosage Forms and Uses |
Non-Patent Citations (2)
Title |
---|
EXPERT OPIN. THER. PATENTS, vol. 20, no. 10, 2010, pages 1389 - 1399 |
See also references of EP2751083A4 |
Cited By (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109593096B (en) * | 2013-03-15 | 2022-01-14 | 因赛特公司 | Tricyclic heterocycles as BET protein inhibitors |
US9624241B2 (en) | 2013-03-15 | 2017-04-18 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
US9227985B2 (en) | 2013-03-15 | 2016-01-05 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
US10464947B2 (en) | 2013-03-15 | 2019-11-05 | Incyte Holdings Corporation | Tricyclic heterocycles as BET protein inhibitors |
CN109593096A (en) * | 2013-03-15 | 2019-04-09 | 因赛特公司 | Tricyclic heterocyclic as BET protein inhibitor |
JP2016513716A (en) * | 2013-03-15 | 2016-05-16 | インサイト・コーポレイションIncyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
US10919912B2 (en) | 2013-03-15 | 2021-02-16 | Incyte Holdings Corporation | Tricyclic heterocycles as BET protein inhibitors |
US11498926B2 (en) | 2013-03-15 | 2022-11-15 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
US9938294B2 (en) | 2013-03-15 | 2018-04-10 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
WO2014178008A1 (en) | 2013-05-02 | 2014-11-06 | Actelion Pharmaceuticals Ltd | Quinolone derivatives |
US9540399B2 (en) | 2013-05-02 | 2017-01-10 | Actelion Pharmaceuticals Ltd. | Quinolone derivatives |
US9290514B2 (en) | 2013-07-08 | 2016-03-22 | Incyte Holdings Corporation | Tricyclic heterocycles as BET protein inhibitors |
US9533997B2 (en) | 2013-07-08 | 2017-01-03 | Incyte Holdings Corporation | Tricyclic heterocycles as BET protein inhibitors |
US9850257B2 (en) | 2013-07-08 | 2017-12-26 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
WO2015050989A2 (en) | 2013-10-01 | 2015-04-09 | Cs Therapeutics Inc. | Macrocyclic compounds for the treatment of proliferative diseases |
US9315501B2 (en) | 2013-11-26 | 2016-04-19 | Incyte Corporation | Bicyclic heterocycles as BET protein inhibitors |
US9737516B2 (en) | 2013-11-26 | 2017-08-22 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
US9918990B2 (en) | 2013-11-26 | 2018-03-20 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
US9399640B2 (en) | 2013-11-26 | 2016-07-26 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
US9777003B2 (en) | 2013-12-19 | 2017-10-03 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
US11091484B2 (en) | 2013-12-19 | 2021-08-17 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
US9309246B2 (en) | 2013-12-19 | 2016-04-12 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
US10442803B2 (en) | 2013-12-19 | 2019-10-15 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
US11059821B2 (en) | 2014-04-23 | 2021-07-13 | Incyte Corporation | 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins |
US9540368B2 (en) | 2014-04-23 | 2017-01-10 | Incyte Corporation | 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins |
US11702416B2 (en) | 2014-04-23 | 2023-07-18 | Incyte Corporation | 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins |
US10781209B2 (en) | 2014-04-23 | 2020-09-22 | Incyte Corporation | 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins |
US10472358B2 (en) | 2014-04-23 | 2019-11-12 | Incyte Corporation | 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins |
US9957268B2 (en) | 2014-04-23 | 2018-05-01 | Incyte Corporation | 1H-pyrrolo[2,3,c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins |
US10227359B2 (en) | 2014-09-15 | 2019-03-12 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
US9527864B2 (en) | 2014-09-15 | 2016-12-27 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
US10618910B2 (en) | 2014-09-15 | 2020-04-14 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
US9834565B2 (en) | 2014-09-15 | 2017-12-05 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
US10322110B2 (en) | 2014-12-04 | 2019-06-18 | Procomcure Biotech Gmbh | Imidazole-based antimicrobial agents |
US10456379B2 (en) | 2014-12-04 | 2019-10-29 | Procomcure Biotech Gmbh | Imidazole-based antimicrobial agents |
US10314820B2 (en) | 2014-12-04 | 2019-06-11 | Procomcure Biotech Gmbh | Imidazole-based heterocyclic compounds |
KR102123365B1 (en) * | 2015-07-28 | 2020-06-16 | 바이옴 테라퓨틱스 리미티드 | Antibacterial treatment and prevention |
WO2017017631A3 (en) * | 2015-07-28 | 2017-04-06 | Vyome Biosciences Pvt. Ltd. | Antibacterial therapeutics and prophylactics |
KR20180037228A (en) * | 2015-07-28 | 2018-04-11 | 바이옴 바이오사이언스 피브이티. 엘티디. | Antibacterial treatment and prevention |
CN108349968A (en) * | 2015-07-28 | 2018-07-31 | 维奥梅生物科学私人有限公司 | Antibacterial therapy agent and prophylactic |
US10329305B2 (en) | 2015-10-29 | 2019-06-25 | Incyte Corporation | Amorphous solid form of a BET protein inhibitor |
US10858372B2 (en) | 2015-10-29 | 2020-12-08 | Incyte Corporation | Amorphous solid form of a BET protein inhibitor |
US12030882B2 (en) | 2016-06-20 | 2024-07-09 | Incyte Corporation | Crystalline solid forms of a bet inhibitor |
US10189832B2 (en) | 2016-06-20 | 2019-01-29 | Incyte Corporation | Crystalline solid forms of a BET inhibitor |
US11091480B2 (en) | 2016-06-20 | 2021-08-17 | Incyte Corporation | Crystalline solid forms of a BET inhibitor |
US10626114B2 (en) | 2016-06-20 | 2020-04-21 | Incyte Corporation | Crystalline solid forms of a BET inhibitor |
US11377446B2 (en) | 2016-06-20 | 2022-07-05 | Incyte Corporation | Crystalline solid forms of a BET inhibitor |
KR20210046015A (en) | 2018-08-13 | 2021-04-27 | 오츠카 세이야쿠 가부시키가이샤 | New medicine for the treatment of inflammatory bowel disease |
WO2020036154A1 (en) | 2018-08-13 | 2020-02-20 | Otsuka Pharmaceutical Co., Ltd. | Novel medicament for treating inflammatory bowel disease |
WO2020163816A1 (en) * | 2019-02-08 | 2020-08-13 | Frequency Therapeutics, Inc. | Quinolin-4-one and 4(1h)-cinnolinone compounds and methods of using same |
WO2021161983A1 (en) | 2020-02-10 | 2021-08-19 | Otsuka Pharmaceutical Co., Ltd. | Novel medicament for treating inflammatory disease |
WO2021161982A1 (en) | 2020-02-10 | 2021-08-19 | Otsuka Pharmaceutical Co., Ltd. | Novel modifying reagents for the presence ratio of intestinal microflora |
WO2021161981A1 (en) | 2020-02-10 | 2021-08-19 | Otsuka Pharmaceutical Co., Ltd. | Novel medicament for treating hepatic encephalopathy |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
WO2023208172A1 (en) * | 2022-04-29 | 2023-11-02 | Beigene , Ltd. | Substituted 7- (pyrimidin-4-yl) quinolin-4 (1h) -one compounds as cyclin dependent kinase inhibitors |
WO2024012421A1 (en) * | 2022-07-11 | 2024-01-18 | Otsuka Pharmaceutical Co., Ltd. | Pharmaceutical compositions comprising a quinolone compound for irritable bowel syndrome |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2012303954B2 (en) | Quinolone compound | |
KR100516379B1 (en) | Novel pyrodonecarboxylic acid derivative or salt thereof and medicine comprising the same as active ingredient | |
WO2014180182A1 (en) | [1,2,4] triazol [4,3-a] pyridine derivate, preparation method therefor or medical application thereof | |
WO2010093341A1 (en) | C-7 isoxazolinyl quinolone/naphthyridine derivatives useful as antibacterial agents | |
JPH02279683A (en) | Substituted azetidinylpyridonecarboxilic acid derivative, its production and pharmaceutical usage | |
NZ620447B2 (en) | Quinolone compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12827305 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 20137018036 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2845459 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2012303954 Country of ref document: AU Date of ref document: 20120830 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012827305 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2014/002338 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2014527483 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14065672 Country of ref document: CO Ref document number: 15187152 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201490530 Country of ref document: EA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014000665 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: IDP00201605385 Country of ref document: ID |
|
ENP | Entry into the national phase |
Ref document number: 112014000665 Country of ref document: BR Kind code of ref document: A2 Effective date: 20140110 |